Yakup YALCIN, Seranat ERİS YALCIN, Selda UYSAL, Burak TATAR, And YAVUZ, Mehmet Ozgur AKKURT, Seyran YİGİT

Investigation of prognostic significance of CD44 expression in women with vulvar squamous cell carcinoma

The aim of our study is to evaluate whether CD 44 isoform expression is a prognostic factor in vulvar carcinom and to correlate the expression with clinicopathological parameters. Methods: The study included 26 patients diagnosed with invasive squamous cell vulvar cancer. The data of patients were obtained from the oncology followup records and the hospital database. The haemotoxylene & eosin stained preparates of the cases were removed from the archives and re-evaluated by examination of the slides under a light microscope. The preparates of the patients were evaluated separately according to the extent and intensity of staining and the combined score applied with the immunohistochemical method in the anti-CD44 antibody in the epithelium and the stroma. Results: When the CD44 epithelial staining intensity and staining combined scores of the patients were examined according to other clinicopathological parameters, a statistically significant difference was found between the groups in terms of tumour grade, differentiation, age, lymph node positivity, and survival rates (p

PDF

___

Jemal A, Siegel R, Ward E, et al. Cancer Statistics. CA Cancer J Clin. 2006;56:106-30.

Leblanc M, Poncelet C, Soriano D, et al. Alteration of CD44 and cadherins expression: possible association with augmented aggressiveness and invasiveness of endometrial carcinoma. Virchows Arch. 2001;438:78–85.

Ingvarsson S, Dahlenborg K, Carlsson R, et al. Co-ligation of CD44 on naive human tonsillar B cells induces progression towards a germinal center phenotype. Int Immunol. 1999;11:739-44.

Liang Y, Fang T, Xu H, et al. Expression of CD44v6 and Livin in gastric cancer tissue. Chin Med J. 2012;125:3161-5.

Hämäläinen K, Kosma VM, Eloranta ML, et al. Downregulated CD44 and hyaluronan expression in vulvar intraepithelial neoplasia and squamous cell carcinomas. Acta Obstet Gynecol Scand. 2010;89:108-19.

Kaufmann M, Heider KH, Sinn HP, et al. CD44 variant exon epotopes in primary breast cancer and length of survival. Lancet. 1995;345:615-9.

Woodman AC, Sugiyama M, Yoshida K, et al. Analysis of anomalous CD44 gene expression in human breast, bladder and colon cancer and correlation of observed mRNA and protein isoforms. Am J Pathol. 1996;149:1519-30.

Galluzzo E, Albi N, Fiorucci S. Involvement of CD44 variant isoform in hyaluronate adhesion by human activated T cells. Eur J Immunol. 1995;25:2932-9.

Xin Y, Grace A, Gallagher MM, et al. CD44v6 in gastric carcinoma: A marker of tumor progression. Appl Immunohistochem Mol Morph. 2001;9:138-42.

10. Yamaguchi A, Goi T, Yu J, et al. Expression of CD44v6 in advenced gastric cancer and its relationship to hematogenous metastasis and long-term prognosis. J Surg Oncol. 2002;79:230-5.

11. Shimbori M, Kijima H, Sato S. Expression of CD44 in primary lung carcinomas using histological and cytological analyses. Anticancer Res. 2003;23:115-21.

12. Lucin K, Matusan K, Dordevic G, et al. Prognostic significance of CD44 molecule in renal cell carcinoma. Croat Med J. 2004;45:703-8.

13. Ma W, Deng Y, Zhou L. The prognostic value of adhesion molecule in women with pimary breast carcinoma: A clinicopathologic study. Clin Oncol. 2005;17:258-63.

14. Lockhart MS, Waldner C, Mongini C, et al. Evaluation of soluble CD44 in patients with breast and colorectal carcinomas and non-Hodgkin’s lymphoma. Oncol Rep. 1999;6:1129-33.

15. Toma V, Hauri D, Schmid U, et al. Focal loss of CD44 variant protein expression is related to recurrence in superficial bladder carsinoma. Am J Pathol. 1999;155:1427-32.

16. Comito MA, Savell VH, Cohen MB. CD44 expression in neuroblastoma and related tumors. J Pediatr Hematol Oncol. 1997;19:292-6.

17. Hong SC, Song JY, Lee JK, et al. Significance of CD44v6 expression in gynecologic malignancies. J Obstet Gynaecol Res. 2006;32:379-86.

18. Tempfer C, Gitsch G, Haeusler G, et al. Prognostic value of immunohistochemically detected CD44 expression in patients with carcinoma of the vulva. Cancer. 1996;78:273-7.

19. Tempfer C, Sliutz G, Haeusler G, et al. CD44v3 and v6 variant isoform expression correlates with poor prognosis in early-stage vulvar cancer. Br J Cancer. 1998;78:1091-4.

20. Hefler L, Concin N, Mincham D, et al. The Prognostic Value of Immunohistochemically Detected CD44v3 and CD44v6 Expression in Patients with Surgically Staged Vulvar Carcinoma. A Multicenter Study American Cancer Society. Cancer. 2002;94:125–30..